Gilead Sciences has been knocked back in its quest to bring the first drug therapy for hepatitis D virus (HDV) to the US market, after the FDA rejected its marketing application.
Thousands of people in the UK will be screened for hepatitis C virus in a new pilot aimed at expanding use of antiviral therapies to eradicate the infectious – and eliminate it altogether
According to the World Health Organization (WHO), approximately 296 million people globally live with hepatitis B, with most unaware of their infection.
Gilead Sciences is planning to file for approval of Hepcludex, its antiviral therapy for rare hepatitis D virus (HDV) in the US later this year, after the drug's safety and efficacy was sho
India’s Zydus Cadila wants to test a form of interferon, usually used against hepatitis B and C, as a potential treatment for the virus that causes COVID-19.
The FDA has approved Akebia Therapeutics’ vadadustat as a treatment for anaemia caused by chronic kidney disease (CKD) in dialysis patients, becoming the first rival to GS